Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Sci Rep ; 13(1): 10342, 2023 08 21.
Article in English | MEDLINE | ID: mdl-37604847

ABSTRACT

African swine fever virus (ASFV) is a lethal animal pathogen that enters its host cells through endocytosis. So far, host factors specifically required for ASFV replication have been barely identified. In this study a genome-wide CRISPR/Cas9 knockout screen in porcine cells indicated that the genes RFXANK, RFXAP, SLA-DMA, SLA-DMB, and CIITA are important for productive ASFV infection. The proteins encoded by these genes belong to the major histocompatibility complex II (MHC II), or swine leucocyte antigen complex II (SLA II). RFXAP and CIITA are MHC II-specific transcription factors, whereas SLA-DMA/B are subunits of the non-classical MHC II molecule SLA-DM. Targeted knockout of either of these genes led to severe replication defects of different ASFV isolates, reflected by substantially reduced plating efficiency, cell-to-cell spread, progeny virus titers and viral DNA replication. Transgene-based reconstitution of SLA-DMA/B fully restored the replication capacity demonstrating that SLA-DM, which resides in late endosomes, plays a crucial role during early steps of ASFV infection.


Subject(s)
African Swine Fever Virus , African Swine Fever , Craniocerebral Trauma , Animals , Swine , African Swine Fever Virus/genetics , DNA Replication , DNA, Viral , Virus Replication/genetics , Histocompatibility Antigens Class II/genetics , Membrane Proteins , Major Histocompatibility Complex , African Swine Fever/genetics
2.
PLoS Pathog ; 17(12): e1010107, 2021 12.
Article in English | MEDLINE | ID: mdl-34879119

ABSTRACT

In contrast to wild type bovine viral diarhea virus (BVDV) specific double deletion mutants are not able to establish persistent infection upon infection of a pregnant heifer. Our data shows that this finding results from a defect in transfer of the virus from the mother animal to the fetus. Pregnant heifers were inoculated with such a double deletion mutant or the parental wild type virus and slaughtered pairwise on days 6, 9, 10 and 13 post infection. Viral RNA was detected via qRT-PCR and RNAscope analyses in maternal tissues for both viruses from day 6 p.i. on. However, the double deletion mutant was not detected in placenta and was only found in samples from animals infected with the wild type virus. Similarly, high levels of wild type viral RNA were present in fetal tissues whereas the genome of the double deletion mutant was not detected supporting the hypothesis of a specific inhibition of mutant virus replication in the placenta. We compared the induction of gene expression upon infection of placenta derived cell lines with wild type and mutant virus via gene array analysis. Genes important for the innate immune response were strongly upregulated by the mutant virus compared to the wild type in caruncle epithelial cells that establish the cell layer on the maternal side at the maternal-fetal interface in the placenta. Also, trophoblasts which can be found on the fetal side of the interface showed significant induction of gene expression upon infection with the mutant virus although with lower complexity. Growth curves recorded in both cell lines revealed a general reduction of virus replication in caruncular epithelial cells compared to the trophoblasts. Compared to the wild type virus this effect was dramtic for the mutant virus that reached only a TCID50 of 1.0 at 72 hours post infection.


Subject(s)
Bovine Virus Diarrhea-Mucosal Disease/transmission , Diarrhea Viruses, Bovine Viral/genetics , Infectious Disease Transmission, Vertical , Placenta/immunology , Placenta/virology , Animals , Cattle , Female , Pregnancy , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , Virus Replication
3.
Pathogens ; 9(11)2020 Nov 23.
Article in English | MEDLINE | ID: mdl-33238521

ABSTRACT

Understanding African swine fever virus (ASFV) transmission is essential for strategies to minimize virus spread during an outbreak. ASFV can survive for extended time periods in animal products, carcasses, and the environment. While the ASFV genome was found in environments around infected farms, data on the virus survival in soil are scarce. We investigated different soil matrices spiked with ASFV-positive blood from infected wild boar to see if ASFV can remain infectious in the soil beneath infected carcasses. As expected, ASFV genome detection was possible over the entire sampling period. Soil pH, structure, and ambient temperature played a role in the stability of infectious ASFV. Infectious ASFV was demonstrated in specimens originating from sterile sand for at least three weeks, from beach sand for up to two weeks, from yard soil for one week, and from swamp soil for three days. The virus was not recovered from two acidic forest soils. All risk mitigation experiments with citric acid or calcium hydroxide resulted in complete inactivation. In conclusion, the stability of infectious ASFV is very low in acidic forest soils but rather high in sandy soils. However, given the high variability, treatment of carcass collection points with disinfectants should be considered.

4.
Pathogens ; 9(2)2020 Feb 17.
Article in English | MEDLINE | ID: mdl-32079312

ABSTRACT

Inactivated whole-virus vaccines are widely used for the control of foot-and-mouth disease (FMD). Their production requires the growth of large quantities of virulent FMD virus in biocontainment facilities, which is expensive and carries the risk of an inadvertent release of virus. Attenuated recombinant viruses lacking the leader protease coding region have been proposed as a safer alternative for the production of inactivated FMD vaccines (Uddowla et al., 2012, J Virol 86:11675-85). In addition to the leader deletion, the marker vaccine virus FMDV LL3BPVKV3DYR A24 encodes amino acid substitutions in the viral proteins 3B and 3D that allow the differentiation of infected from vaccinated animals and has been previously shown to be effective in cattle and pigs. In the present study, two groups of six pigs each were inoculated with live FMDV LL3BPVKV3DYR A24 virus either intradermally into the heel bulb (IDHB) or by intra-oropharyngeal (IOP) deposition. The animals were observed for 3 or 5 days after inoculation, respectively. Serum, oral and nasal swabs were collected daily and a thorough postmortem examination with tissue collection was performed at the end of the experiment. None of the animals had any signs of disease or virus shedding. Virus was reisolated from only one serum sample (IDHB group, sample taken on day 1) and one piece of heel bulb skin from the inoculation site of another animal (IDHB group, necropsy on day 3), confirming that FMDV LL3BPVKV3DYR A24 is highly attenuated in pigs.

5.
Vaccine ; 36(29): 4181-4187, 2018 07 05.
Article in English | MEDLINE | ID: mdl-29895502

ABSTRACT

Classical swine fever (CSF) remains as one of the most important infectious diseases of swine. While prophylactic vaccination is usually prohibited in free countries with industrialized pig production, emergency vaccination is still foreseen. In this context, marker vaccines are preferred as they can reduce the impact on trade. The live-attenuated Suvaxyn® CSF Marker vaccine by Zoetis (based on pestivirus chimera "CP7_E2alf"), was recently licensed by the European Medicines Agency. Its efficacy for the individual animal had been shown in prior studies, but questions remained regarding protection against transplacental transmission. To answer this question, a trial with eight pregnant sows and their offspring was performed as prescribed by the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Six of the sows were intramuscularly vaccinated on day 44 of gestation, while the other two remained as unvaccinated controls. All sows were challenged with the moderately virulent CSFV strain "Roesrath" and euthanized shortly before the calculated farrowing date. Sows and piglets were grossly examined and necropsied. Organs (spleen, tonsil, lymph node, and kidney), EDTA-blood and serum were collected from all animals. All samples were tested for antibodies against CSFV glycoproteins E2 and Erns as well as CSFV (virus, antigen and genome). It could be demonstrated that the vaccine complies with all requirements, i.e. no virus was found in the blood of vaccinated sows and their fetuses, and no antibodies were found in the serum of the fetuses from the vaccinated sows. All controls were valid. Thus, it was demonstrated that a single dose vaccination in the sows efficiently protected the offspring against transplacental infection with a moderately virulent CSFV strain.


Subject(s)
Classical Swine Fever Virus/immunology , Classical Swine Fever/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/prevention & control , Viral Vaccines/administration & dosage , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Blood/virology , Classical Swine Fever/pathology , Female , Injections, Intramuscular , Pregnancy , Pregnancy Complications, Infectious/pathology , Swine , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology , Vaccines, Marker/administration & dosage , Vaccines, Marker/immunology
6.
Sci Rep ; 8(1): 6510, 2018 04 25.
Article in English | MEDLINE | ID: mdl-29695831

ABSTRACT

African swine fever (ASF) was introduced into the Eastern European Union in 2014 and led to considerable mortality among wild boar. In contrast, unexpected high antibody prevalence was reported in hunted wild boar in north-eastern Estonia. One of the causative virus strains was recently characterized. While it still showed rather high virulence in the majority of experimentally infected animals, one animal survived and recovered completely. Here, we report on the follow-up characterization of the isolate obtained from the survivor in the acute phase of infection. As a first step, three in vivo experiments were performed with different types of pigs: twelve minipigs (trial A), five domestic pigs (trial B), and five wild boar (trial C) were inoculated. 75% of the minipigs and all domestic pigs recovered after an acute course of disease. However, all wild boar succumbed to infection within 17 days. Representative samples were sequenced using NGS-technologies, and whole-genomes were compared to ASFV "Georgia 2007/1". The alignments indicated a deletion of 14560 base pairs at the 5' end, and genome reorganization by duplication. The characteristic deletion was confirmed in all trial samples and local field samples. In conclusion, an ASFV variant was found in Estonia that showed reduced virulence.


Subject(s)
African Swine Fever Virus/genetics , Sequence Deletion/genetics , African Swine Fever/virology , Animals , Cell Line , Estonia , Gene Deletion , Leukocytes, Mononuclear/virology , Phenotype , Sus scrofa/virology , Swine/virology , Swine, Miniature/virology , Virulence/genetics
7.
PLoS One ; 12(5): e0177433, 2017.
Article in English | MEDLINE | ID: mdl-28542321

ABSTRACT

Prophylactic vaccination using live attenuated classical swine fever (CSF) vaccines has been a very effective method to control the disease in endemic regions and during outbreaks in previously disease-free areas. These vaccines confer effective protection against the disease at early times post-vaccination although the mechanisms mediating the protection are poorly characterized. Here we present the events occurring after the administration of our in-house developed live attenuated marker vaccine, FlagT4Gv. We previously reported that FlagT4Gv intramuscular (IM) administered conferred effective protection against intranasal challenge with virulent CSFV (BICv) as early as 7 days post-vaccination. Here we report that FlagT4Gv is able to induce protection against disease as early as three days post-vaccination. Immunohistochemical testing of tissues from FlagT4Gv-inoculated animals showed that tonsils were colonized by the vaccine virus by day 3 post-inoculation. There was a complete absence of BICv in tonsils of FlagT4Gv-inoculated animals which had been intranasal (IN) challenged with BICv 3 days after FlagT4Gv infection, confirming that FlagT4Gv inoculation confers sterile immunity. Analysis of systemic levels of 19 different cytokines in vaccinated animals demonstrated an increase of IFN-α three days after FlagT4Gv inoculation compared with mock infected controls.


Subject(s)
Classical Swine Fever Virus/immunology , Classical Swine Fever/immunology , Classical Swine Fever/prevention & control , Viral Vaccines/pharmacology , Animals , Classical Swine Fever/virology , Classical Swine Fever Virus/pathogenicity , Classical Swine Fever Virus/physiology , Cytokines/blood , Female , Interferon-alpha/blood , Palatine Tonsil/immunology , Palatine Tonsil/virology , Sus scrofa , Swine , Time Factors , Vaccines, Attenuated/pharmacology , Vaccines, Marker/pharmacology , Virus Replication
8.
Viruses ; 9(4)2017 04 21.
Article in English | MEDLINE | ID: mdl-28430168

ABSTRACT

Classical swine fever (CSF) remains one of the most important transboundary viral diseases of swine worldwide. The causative agent is CSF virus, a small, enveloped RNA virus of the genus Pestivirus. Based on partial sequences, three genotypes can be distinguished that do not, however, directly correlate with virulence. Depending on both virus and host factors, a wide range of clinical syndromes can be observed and thus, laboratory confirmation is mandatory. To this means, both direct and indirect methods are utilized with an increasing degree of commercialization. Both infections in domestic pigs and wild boar are of great relevance; and wild boars are a reservoir host transmitting the virus sporadically also to pig farms. Control strategies for epidemic outbreaks in free countries are mainly based on classical intervention measures; i.e., quarantine and strict culling of affected herds. In these countries, vaccination is only an emergency option. However, live vaccines are used for controlling the disease in endemically infected regions in Asia, Eastern Europe, the Americas, and some African countries. Here, we will provide a concise, updated review on virus properties, clinical signs and pathology, epidemiology, pathogenesis and immune responses, diagnosis and vaccination possibilities.


Subject(s)
Classical Swine Fever Virus/classification , Classical Swine Fever Virus/physiology , Classical Swine Fever/epidemiology , Classical Swine Fever/virology , Host-Pathogen Interactions , Animals , Classical Swine Fever/pathology , Classical Swine Fever Virus/genetics , Communicable Disease Control/methods , Disease Outbreaks , Genotype , Global Health , Sus scrofa , Swine
9.
J Virol ; 91(1)2017 Jan 01.
Article in English | MEDLINE | ID: mdl-27795430

ABSTRACT

African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for the swine industry. The control of African swine fever (ASF) has been hampered by the unavailability of vaccines. Successful experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFV. Recombinant viruses harboring engineered deletions of specific virulence-associated genes induce solid protection against challenge with parental viruses. Deletion of the 9GL (B119L) gene in the highly virulent ASFV isolates Malawi Lil-20/1 (Mal) and Pretoriuskop/96/4 (Δ9GL viruses) resulted in complete protection when challenged with parental isolates. When similar deletions were created within the ASFV Georgia 2007 (ASFV-G) genome, attenuation was achieved but the protective and lethal doses were too similar. To enhance attenuation of ASFV-G, we deleted another gene, UK (DP96R), which was previously shown to be involved in attenuation of the ASFV E70 isolate. Here, we report the construction of a double-gene-deletion recombinant virus, ASFV-G-Δ9GL/ΔUK. When administered intramuscularly (i.m.) to swine, there was no induction of disease, even at high doses (106 HAD50). Importantly, animals infected with 104 50% hemadsorbing doses (HAD50) of ASFV-G-Δ9GL/ΔUK were protected as early as 14 days postinoculation when challenged with ASFV-G. The presence of protection correlates with the appearance of serum anti-ASFV antibodies, but not with virus-specific circulating ASFV-specific gamma interferon (IFN-γ)-producing cells. ASFV-G-Δ9GL/ΔUK is the first rationally designed experimental ASFV vaccine that protects against the highly virulent ASFV Georgia 2007 isolate as early as 2 weeks postvaccination. IMPORTANCE: Currently, there is no commercially available vaccine against African swine fever. Outbreaks of the disease are devastating to the swine industry and are caused by circulating strains of African swine fever virus. Here, we report a putative vaccine derived from a currently circulating strain but containing two deletions in two separate areas of the virus, allowing increased safety. Using this genetically modified virus, we were able to vaccinate swine and protect them from developing ASF. We were able to achieve protection from disease as early as 2 weeks after vaccination, even when the pigs were exposed to a higher than normal concentration of ASFV.


Subject(s)
African Swine Fever Virus/genetics , African Swine Fever Virus/pathogenicity , African Swine Fever/prevention & control , Antibodies, Viral/biosynthesis , Viral Proteins/immunology , Viral Vaccines/administration & dosage , African Swine Fever/immunology , African Swine Fever/virology , African Swine Fever Virus/drug effects , African Swine Fever Virus/immunology , Amino Acid Sequence , Animals , Antibodies, Neutralizing/biosynthesis , Cytokines/biosynthesis , Cytokines/immunology , Dose-Response Relationship, Immunologic , Gene Deletion , Gene Expression , Immunogenicity, Vaccine , Injections, Intramuscular , Sequence Alignment , Swine , Time Factors , Vaccines, Synthetic , Viral Proteins/genetics , Viral Vaccines/biosynthesis , Viral Vaccines/genetics , Virulence
10.
Viruses ; 8(10)2016 10 22.
Article in English | MEDLINE | ID: mdl-27782090

ABSTRACT

African swine fever (ASF) is a lethal hemorrhagic disease of swine caused by a double-stranded DNA virus, ASF virus (ASFV). There is no vaccine to prevent the disease and current control measures are limited to culling and restricting animal movement. Swine infected with attenuated strains are protected against challenge with a homologous virulent virus, but there is limited knowledge of the host immune mechanisms generating that protection. Swine infected with Pretoriuskop/96/4 (Pret4) virus develop a fatal severe disease, while a derivative strain lacking virulence-associated gene 9GL (Pret4Δ9GL virus) is completely attenuated. Swine infected with Pret4Δ9GL virus and challenged with the virulent parental virus at 7, 10, 14, 21, and 28 days post infection (dpi) showed a progressive acquisition of protection (from 40% at 7 dpi to 80% at 21 and 28 dpi). This animal model was used to associate the presence of host immune response (ASFV-specific antibody and interferon (IFN)-γ responses, or specific cytokine profiles) and protection against challenge. With the exception of ASFV-specific antibodies in survivors challenged at 21 and 28 dpi, no association between the parameters assessed and protection could be established. These results, encompassing data from 65 immunized swine, underscore the complexity of the system under study, suggesting that protection relies on the concurrence of different host immune mechanisms.


Subject(s)
African Swine Fever Virus/immunology , African Swine Fever/immunology , African Swine Fever/prevention & control , Animals , Antibodies, Viral/blood , Cytokines/metabolism , Leukocytes, Mononuclear/immunology , Swine
11.
Virus Res ; 223: 181-9, 2016 09 02.
Article in English | MEDLINE | ID: mdl-27497620

ABSTRACT

African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal disease of domestic pigs that has significant economic consequences for the swine industry. The viral genome encodes for more than 150 genes, and only a select few of these genes have been studied in some detail. Here we report the characterization of open reading frame Ep152R that has a predicted complement control module/SCR domain. This domain is found in Vaccinia virus proteins that are involved in blocking the immune response during viral infection. A recombinant ASFV harboring a HA tagged version of the Ep152R protein was developed (ASFV-G-Ep152R-HA) and used to demonstrate that Ep152R is an early virus protein. Attempts to construct recombinant viruses having a deleted Ep152R gene were consistently unsuccessful indicating that Ep152R is an essential gene. Interestingly, analysis of host-protein interactions for Ep152R using a yeast two-hybrid screen, identified BAG6, a protein previously identified as being required for ASFV replication. Furthermore, fluorescent microscopy analysis confirms that Ep152R-BAG6 interaction actually occurs in cells infected with ASFV.


Subject(s)
African Swine Fever Virus/physiology , African Swine Fever/metabolism , African Swine Fever/virology , Genes, Essential , Molecular Chaperones/metabolism , Viral Proteins/genetics , Viral Proteins/metabolism , Amino Acid Sequence , Animals , Cells, Cultured , Conserved Sequence , Host-Pathogen Interactions , Macrophages/metabolism , Macrophages/virology , Models, Molecular , Molecular Chaperones/chemistry , Molecular Chaperones/genetics , Open Reading Frames , Protein Binding , Protein Conformation , Protein Interaction Mapping/methods , Protein Transport , Sequence Deletion , Swine , Two-Hybrid System Techniques , Viral Proteins/chemistry , Virus Replication
12.
Virus Res ; 221: 8-14, 2016 08 02.
Article in English | MEDLINE | ID: mdl-27182007

ABSTRACT

African swine fever virus (ASFV) produces a contagious disease of domestic pigs that results in severe economic consequences to the swine industry. Control of the disease has been hampered by the unavailability of vaccines. We recently reported the development of two experimental vaccine strains (ASFV-G-Δ9GL and ASFV-G-ΔMGF) based on the attenuation of the highly virulent and epidemiologically relevant Georgia2007 isolate. Deletion of the 9GL gene or six genes of the MGF360/505 group produced two attenuated ASFV strains which were able to confer protection to animals when challenged with the virulent parental virus. Both viruses, although efficient in inducing protection, present concerns regarding their safety. In an attempt to solve this problem we developed a novel virus strain, ASFV-G-Δ9GL/ΔMGF, based on the deletion of all genes deleted in ASFV-G-Δ9GL and ASFV-G-ΔMGF. ASFV-G-Δ9GL/ΔMGF is the first derivative of a highly virulent ASFV field strain subjected to a double round of recombination events seeking to sequentially delete specific genes. ASFV-G-Δ9GL/ΔMGF showed a decreased ability to replicate in primary swine macrophage cultures relative to that of ASFV-G and ASFV-G-ΔMGF but similar to that of ASFV-G-Δ9GL. ASFV-G-Δ9GL/ΔMGF was attenuated when intramuscularly inoculated into swine, even at doses as high as 10(6) HAD50. Animals infected with doses ranging from 10(2) to 10(6) HAD50 did not present detectable levels of virus in blood at any time post-infection and they did not develop detectable levels of anti-ASFV antibodies. Importantly, ASFV-G-Δ9GL/ΔMGF does not induce protection against challenge with the virulent parental ASFV-G isolate. Results presented here suggest caution towards approaches involving genomic manipulations when developing rationally designed ASFV vaccine strains.


Subject(s)
African Swine Fever Virus/genetics , African Swine Fever Virus/pathogenicity , African Swine Fever/pathology , African Swine Fever/virology , Sequence Deletion , Viral Proteins/genetics , Viral Vaccines/immunology , African Swine Fever/prevention & control , African Swine Fever Virus/immunology , African Swine Fever Virus/physiology , Animals , Antibodies, Viral/blood , Cells, Cultured , Georgia , Injections, Intramuscular , Macrophages/virology , Recombination, Genetic , Swine , Treatment Outcome , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/genetics , Vaccines, Attenuated/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/genetics , Virulence , Virus Replication
13.
Virology ; 494: 178-89, 2016 07.
Article in English | MEDLINE | ID: mdl-27110709

ABSTRACT

Controlling classical swine fever (CSF) mainly involves vaccination with live attenuated vaccines (LAV). Experimental CSFV LAVs has been lately developed through reverse genetics using several different approaches. Here we present that codon de-optimization in the major CSFV structural glycoprotein E2 coding region, causes virus attenuation in swine. Four different mutated constructs (pCSFm1-pCSFm4) were designed using various mutational approaches based on the genetic background of the highly virulent strain Brescia (BICv). Three of these constructs produced infectious viruses (CSFm2v, CSFm3v, and CSFm4v). Animals infected with CSFm2v presented a reduced and extended viremia but did not display any CSF-related clinical signs. Animals that were infected with CSFm2v were protected against challenge with virulent parental BICv. This is the first report describing the development of an attenuated CSFV experimental vaccine by codon usage de-optimization, and one of the few examples of virus attenuation using this methodology that is assessed in a natural host.


Subject(s)
Classical Swine Fever Virus/genetics , Classical Swine Fever Virus/immunology , Classical Swine Fever/prevention & control , Vaccines, Attenuated/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Animals , Base Sequence , Cell Line , Cells, Cultured , Classical Swine Fever/immunology , Classical Swine Fever/mortality , Classical Swine Fever/virology , Codon , Computational Biology/methods , Gene Expression Profiling , Gene Expression Regulation , Host-Pathogen Interactions , Mutation , Swine , Vaccines, Attenuated/genetics , Viral Envelope Proteins/chemistry , Viral Vaccines/genetics , Virulence/genetics , Virus Replication
14.
J Virol ; 89(16): 8556-66, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26063424

ABSTRACT

UNLABELLED: African swine fever virus (ASFV) is the etiological agent of an often lethal disease of domestic pigs. Disease control strategies have been hampered by the unavailability of vaccines against ASFV. Since its introduction in the Republic of Georgia, a highly virulent virus, ASFV Georgia 2007 (ASFV-G), has caused an epizootic that spread rapidly into Eastern European countries. Currently no vaccines are available or under development to control ASFV-G. In the past, genetically modified ASFVs harboring deletions of virulence-associated genes have proven attenuated in swine, inducing protective immunity against challenge with homologous parental viruses. Deletion of the gene 9GL (open reading frame [ORF] B119L) in highly virulent ASFV Malawi-Lil-20/1 produced an attenuated phenotype even when administered to pigs at 10(6) 50% hemadsorption doses (HAD50). Here we report the construction of a genetically modified ASFV-G strain (ASFV-G-Δ9GLv) harboring a deletion of the 9GL (B119L) gene. Like Malawi-Lil-20/1-Δ9GL, ASFV-G-Δ9GL showed limited replication in primary swine macrophages. However, intramuscular inoculation of swine with 10(4) HAD50 of ASFV-G-Δ9GL produced a virulent phenotype that, unlike Malawi-Lil-20/1-Δ9GL, induced a lethal disease in swine like parental ASFV-G. Interestingly, lower doses (10(2) to 10(3) HAD50) of ASFV-G-Δ9GL did not induce a virulent phenotype in swine and when challenged protected pigs against disease. A dose of 10(2) HAD50 of ASFV-G-Δ9GLv conferred partial protection when pigs were challenged at either 21 or 28 days postinfection (dpi). An ASFV-G-Δ9GL HAD50 of 10(3) conferred partial and complete protection at 21 and 28 dpi, respectively. The information provided here adds to our recent report on the first attempts toward experimental vaccines against ASFV-G. IMPORTANCE: The main problem for controlling ASF is the lack of vaccines. Studies on ASFV virulence lead to the production of genetically modified attenuated viruses that induce protection in pigs but only against homologous virus challenges. Here we produced a recombinant ASFV lacking virulence-associated gene 9GL in an attempt to produce a vaccine against virulent ASFV-G, a highly virulent virus isolate detected in the Caucasus region in 2007 and now spreading though the Caucasus region and Eastern Europe. Deletion of 9GL, unlike with other ASFV isolates, did not attenuate completely ASFV-G. However, when delivered once at low dosages, recombinant ASFV-G-Δ9GL induces protection in swine against parental ASFV-G. The protection against ASFV-G is highly effective after 28 days postvaccination, whereas at 21 days postvaccination, animals survived the lethal challenge but showed signs of ASF. Here we report the design and development of an experimental vaccine that induces protection against virulent ASFV-G.


Subject(s)
African Swine Fever Virus/genetics , African Swine Fever Virus/immunology , African Swine Fever/prevention & control , Viral Proteins/genetics , Viral Vaccines/pharmacology , Virulence Factors/genetics , Animals , Base Sequence , DNA Primers/genetics , Gene Deletion , Genetic Engineering/methods , High-Throughput Nucleotide Sequencing , Molecular Sequence Data , Mutation, Missense/genetics , Polymerase Chain Reaction , Swine , Viral Vaccines/genetics
15.
Vet Microbiol ; 172(1-2): 44-50, 2014 Aug 06.
Article in English | MEDLINE | ID: mdl-24856133

ABSTRACT

Rift Valley fever (RVF) is an important viral disease of animals and humans in Africa and the Middle East that is transmitted by mosquitoes. The disease is of concern to international agricultural and public health communities. The RVFV MP-12 strain has been the most safety tested attenuated vaccine strain; thus it is being considered as a potential vaccine for the US national veterinary stockpile. This study was designed to establish safety protocols for large animal research with virulent RVF viruses, establish a target host immune response baseline using RVF MP-12 strain, and independently evaluate this strain as a potential US emergency response vaccine. Ten, approximately four month-old lambs and calves were vaccinated with RVF MP-12 strain; two additional animals per species provided negative control specimens. The animals were monitored for clinical and immune response, fever, and viremia. Two animals per species were sacrificed on 2, 3, 4, 10 and 28 days post infection and full necropsies were performed for histopathological examination. No clinical or febrile responses were observed in this study. The onset and titer of the immune response is discussed. There was no significant histopathology in the lambs; however, 6 out of 10 vaccinated calves had multifocal, random areas of hepatocellular degeneration and necrosis. RVF MP12 antigen was detected in these areas of necrosis by immunohistochemistry in one calf. This study provides independent and baseline information on the RVF MP-12 attenuated vaccination in vaccine relevant age target species and indicates the importance of performing safety testing on vaccine relevant aged target animals.


Subject(s)
Cattle Diseases/prevention & control , Rift Valley Fever/veterinary , Sheep Diseases/prevention & control , Viral Vaccines/immunology , Age Factors , Animals , Antibodies, Viral/blood , Cattle , Cattle Diseases/virology , Host Specificity , Humans , Immunity, Active , Rift Valley Fever/prevention & control , Rift Valley Fever/virology , Rift Valley fever virus/immunology , Sheep , Sheep Diseases/virology , Sheep, Domestic , Vaccination/veterinary , Vaccines, Attenuated , Viral Load , Viral Vaccines/administration & dosage
16.
J Vet Diagn Invest ; 25(1): 72-81, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23345271

ABSTRACT

Brucellosis has emerged as a disease of concern in marine mammals in the last 2 decades. Molecular detection techniques have the potential to address limitations of other methods for detecting infection with Brucella in these species. Presented herein is a real-time polymerase chain reaction (PCR) method targeting the Brucella genus-specific bcsp31 gene. The method also includes a target to a conserved region of the eukaryotic mitochondrial 16S ribosomal RNA gene to assess suitability of extracted DNA and a plasmid-based internal control to detect failure of PCR due to inhibition. This method was optimized and validated to detect Brucella spp. in multiple sample matrices, including fresh or frozen tissue, blood, and feces. The analytical limit of detection was low, with 95% amplification at 24 fg, or an estimated 7 bacterial genomic copies. When Brucella spp. were experimentally added to tissue or fecal homogenates, the assay detected an estimated 1-5 bacteria/µl. An experiment simulating tissue autolysis showed relative persistence of bacterial DNA compared to host mitochondrial DNA. When used to screen 1,658 field-collected marine mammal tissues in comparison to microbial culture, diagnostic sensitivity and specificity were 70.4% and 98.3%, respectively. In addition to amplification in fresh and frozen tissues, Brucella spp. were detected in feces and formalin-fixed, paraffin-embedded tissues from culture-positive animals. Results indicate the utility of this real-time PCR for the detection of Brucella spp. in marine species, which may have applications in surveillance or epidemiologic investigations.


Subject(s)
Brucella/isolation & purification , Brucellosis/veterinary , Cetacea/microbiology , Real-Time Polymerase Chain Reaction/veterinary , Animals , Bottle-Nosed Dolphin/blood , Bottle-Nosed Dolphin/microbiology , Brucella/genetics , Brucellosis/blood , Brucellosis/microbiology , Cetacea/blood , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Feces/microbiology , Phoca/blood , Phoca/microbiology , Real-Time Polymerase Chain Reaction/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...